Vertex Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jefferies Raises Price Target on Vertex Pharma (VRTX) to $107; Reiterates Buy
July 28, 2016 9:07 AM EDTJefferies reiterated a Buy rating on Vertex Pharma (NASDAQ: VRTX), and raised the price target to $107.00 (from $102.00), following the company's 2Q earnings report. Orkambi sales fell slightly short of $249M estimates. Vertex continues to expect persistence and compliance rates on... More
Vertex Pharma (VRTX) Tops Q2 EPS by 3c; Reiterates Outlook
July 27, 2016 4:07 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $426 million versus the consensus estimate of $427.94 million.
Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705... More
